Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AKRO Stock Forecast 2025-2026
$55.62
Current Price
$4.43B
Market Cap
Buy 11
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AKRO Price Targets
+96.0%
To High Target of $109.00
+33.0%
To Median Target of $74.00
+7.9%
To Low Target of $60.00
AKRO Price Momentum
+1.7%
1 Week Change
+43.1%
1 Month Change
+131.9%
1 Year Change
+99.9%
Year-to-Date Change
-4.8%
From 52W High of $58.40
+164.6%
From 52W Low of $21.02
📊 TOP ANALYST CALLS
Did AKRO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Akero is one of their latest high-conviction picks.
Latest AKRO Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, AKRO has a bullish consensus with a median price target of $74.00 (ranging from $60.00 to $109.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $55.62, the median forecast implies a 33.0% upside. This outlook is supported by 11 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Eliana Merle at UBS, projecting a 96.0% upside. Conversely, the most conservative target is provided by Liisa Bayko at Evercore ISI Group, suggesting a 7.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AKRO Analyst Ratings
11
Buy
0
Hold
0
Sell
AKRO Price Target Range
Low
$60.00
Average
$74.00
High
$109.00
Current: $55.62
Latest AKRO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AKRO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 27, 2025 | B of A Securities | Alexandria Hammond | Buy | Maintains | $64.00 |
| May 13, 2025 | Citigroup | Jonathan Woo | Buy | Maintains | $78.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $75.00 |
| Jan 31, 2025 | UBS | Eliana Merle | Buy | Maintains | $109.00 |
| Jan 30, 2025 | B of A Securities | Alexandria Hammond | Buy | Upgrade | $63.00 |
| Jan 28, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $96.00 |
| Jan 28, 2025 | Citigroup | Jonathan Woo | Buy | Maintains | $80.00 |
| Jan 28, 2025 | Canaccord Genuity | Edward Nash | Buy | Maintains | $73.00 |
| Jan 27, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $72.00 |
| Jan 16, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Nov 18, 2024 | Citigroup | Jonathan Woo | Buy | Initiates | $65.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Reiterates | $0.00 |
| Jun 12, 2024 | Cantor Fitzgerald | Prakhar Agrawal | Overweight | Reiterates | $0.00 |
| Jun 11, 2024 | Wolfe Research | Andy Chen | Outperform | Initiates | $0.00 |
| Jun 11, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $50.00 |
| May 15, 2024 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $38.00 |
Akero Therapeutics Inc. (AKRO) Competitors
The following stocks are similar to Akero based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Akero Therapeutics Inc. (AKRO) Financial Data
Akero Therapeutics Inc. has a market capitalization of $4.43B with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -27.9%.
Valuation Metrics
Market Cap
$4.43B
Enterprise Value
$3.78B
P/E Ratio
0.0x
PEG Ratio
-13.1x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+15.5%
Current Ratio
16.8x
Debt/Equity
3.3x
ROE
-27.9%
ROA
-18.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Akero Therapeutics Inc. (AKRO) Business Model
About Akero Therapeutics Inc.
What They Do
Develops treatments for serious metabolic diseases.
Business Model
Akero Therapeutics generates revenue through the development and commercialization of innovative therapeutics targeting metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company focuses on advanced research and development, leveraging scientific insights to create effective treatments that meet significant unmet medical needs.
Additional Information
With a strong emphasis on liver health and function, Akero Therapeutics operates at the forefront of biotechnology and healthcare. The company's dedication to addressing the rising incidence of metabolic disorders positions it as a key player in improving patient outcomes in a critical area of medical science.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
63
CEO
Dr. Andrew Cheng M.D., Ph.D.
Country
United States
IPO Year
2019
Website
akerotx.comAkero Therapeutics Inc. (AKRO) Latest News & Analysis
Latest News
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Akero Therapeutics (NASDAQ:AKRO) investors who bought shares before September 13, 2022. More info is available at their website.
Why It Matters
Legal investigations can indicate potential issues with a company's practices or financials, which may impact stock value and investor confidence in Akero Therapeutics.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Akero Therapeutics (NASDAQ:AKRO) investors who bought shares before September 13, 2022.
Why It Matters
The investigation into Akero Therapeutics may signal potential legal issues or financial irregularities, impacting stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Akero Therapeutics (NASDAQ:AKRO) investors who bought shares before September 13, 2022. More info at bgandg.com/AKRO.
Why It Matters
The investigation into Akero Therapeutics may signal potential legal issues, affecting stock performance and investor confidence in the company.
Source: Accesswire
Market Sentiment:
Neutral
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
13 days ago
Quick Summary
Akero Therapeutics (Nasdaq: AKRO) will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 2:40 p.m. E.T.
Why It Matters
Akero Therapeutics' presentation at a major healthcare conference could highlight its developments and attract investor interest, potentially impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Akero Therapeutics (NASDAQ:AKRO) investors who bought shares before September 13, 2022.
Why It Matters
The investigation into Akero Therapeutics may signal potential legal issues, which could impact the company's stock performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Akero Therapeutics (NASDAQ:AKRO) investors who bought shares before September 13, 2022. More info is available at bgandg.com/AKRO.
Why It Matters
The investigation into Akero Therapeutics may indicate potential legal issues, impacting stock performance and investor confidence, particularly for those who bought shares before September 2022.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About AKRO Stock
What is Akero Therapeutics Inc.'s (AKRO) stock forecast for 2025?
Based on our analysis of 13 Wall Street analysts, Akero Therapeutics Inc. (AKRO) has a median price target of $74.00. The highest price target is $109.00 and the lowest is $60.00.
Is AKRO stock a good investment in 2025?
According to current analyst ratings, AKRO has 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $55.62. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AKRO stock?
Wall Street analysts predict AKRO stock could reach $74.00 in the next 12 months. This represents a 33.0% increase from the current price of $55.62. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Akero Therapeutics Inc.'s business model?
Akero Therapeutics generates revenue through the development and commercialization of innovative therapeutics targeting metabolic diseases, particularly non-alcoholic steatohepatitis (NASH). The company focuses on advanced research and development, leveraging scientific insights to create effective treatments that meet significant unmet medical needs.
What is the highest forecasted price for AKRO Akero Therapeutics Inc.?
The highest price target for AKRO is $109.00 from Eliana Merle at UBS, which represents a 96.0% increase from the current price of $55.62.
What is the lowest forecasted price for AKRO Akero Therapeutics Inc.?
The lowest price target for AKRO is $60.00 from Liisa Bayko at Evercore ISI Group, which represents a 7.9% increase from the current price of $55.62.
What is the overall AKRO consensus from analysts for Akero Therapeutics Inc.?
The overall analyst consensus for AKRO is bullish. Out of 13 Wall Street analysts, 11 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $74.00.
How accurate are AKRO stock price projections?
Stock price projections, including those for Akero Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2025 9:48 AM UTC